Data Insights
By Company Name
No filters selected
By Disease Name
No filters selected
By Drug Name
No filters selected
By Themes
No filters selected
Showing 2 results out of 2
Data Insights
Risk adjusted net present value: What is the current valuation of Novartis's LNA-043?
LNA-043 is a biologic commercialized by Novartis, with a leading Phase II program in Osteoarthritis. According to Globaldata, it is...
Data Insights
Risk adjusted net present value: What is the current valuation of Novartis's LNA-043?
LNA-043 is a biologic commercialized by Novartis, with a leading Phase II program in Osteoarthritis. According to Globaldata, it is...